NEUROLOGIX, INC. (A Development Stage Company) STATEMENTS OF OPERATIONS (UNAUDITED) (Amounts in thousands, except share and per share amounts) | ||||
Three Months EndedMarch 31, | For the period February 12, 1999(inception) throughMarch 31, 2011 | |||
2011 | 2010 | |||
Revenues | $ - | $ - | $ - | |
Operating expenses: | ||||
Research and development | 1,227 | 1,857 | 34,723 | |
General and administrative expenses | 830 | 1,284 | 23,044 | |
Loss from operations | (2,057) | (3,141) | (57,767) | |
Other (expense) income: | ||||
Dividend, interest and other income | - | - | 1,885 | |
Interest expense – related parties | (1,368) | - | (2,234) | |
Change in estimated fair value of derivative financial instruments – warrants | 1,343 | (356) | (1,892) | |
Other (expense) income, net | (25) | (356) | (2,241) | |
Net loss | (2,082) | (3,497) | $(60,008) | |
Preferred stock dividends | (828) | (771) | ||
Net loss applicable to common stock | $(2,910) | $(4,268) | ||
Net loss applicable to common stock per share, basic and diluted | $(0.10) | $(0.15) | ||
Weighted average common shares outstanding, basic and diluted | 27,918,148 | 27,865,010 | ||